☆ 4.6 Editorial Material

Re: First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma Navigating Metastatic Urothelial Cancer with Nectin-4 PET/CT

EUROPEAN UROLOGY (2023)

First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma

Xiaojiang Duan et al.

Summary: This study developed a bicyclic peptide-based radiotracer Ga-68-N188 for targeting Nectin-4 and conducted preclinical and translational studies. The results demonstrated that Ga-68-N188 has high affinity and specific uptake for Nectin-4, and can quantitatively image the expression level of Nectin-4 in different organs. The findings of this study provide a companion diagnostic tool for treatments targeting Nectin-4.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Niklas Kluemper et al.

Summary: A study on EV treatment for metastatic urothelial carcinoma revealed that membranous NECTIN-4 protein expression significantly decreases during metastatic spread. Absence or weak expression of NECTIN-4 is associated with a significantly shortened progression-free survival on EV treatment, suggesting the importance of determining NECTIN-4 receptor status before initiating EV.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors

Michael Rigby et al.

Summary: Nectin-4 is overexpressed in multiple tumor types, and BT8009, a new drug targeting Nectin-4, exhibits significant antitumor activity and good tolerability in solid tumors expressing Nectin-4.

MOLECULAR CANCER THERAPEUTICS (2022)

添加到收藏夹

Article Medicine, General & Internal

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Thomas Powles et al.

Summary: Enfortumab vedotin significantly prolonged survival compared with standard chemotherapy in patients with advanced urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor, as well as showing better progression-free survival outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Jonathan Rosenberg et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Re: First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma Navigating Metastatic Urothelial Cancer with Nectin-4 PET/CT

相关参考文献

First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

导出引文

分享论文